公开(公告)号：US20050165097A1

公开(公告)日：2005-07-28

申请号：US11081640

申请日：2005-03-17

申请人： Eckard Weber ,  Howard Katz

发明人： Eckard Weber ,  Howard Katz

IPC分类号： A61K45/06 ,  A61K20060101 ,  A61K31/135 ,  A61K31/137 ,  A61K31/165 ,  A61K31/166 ,  A61K31/167 ,  A61K31/24 ,  A61K31/415 ,  A61K31/417 ,  A61K31/44 ,  A61K31/445 ,  A61K31/505 ,  A61K38/46 ,  A61P23/02 ,  A61P43/00 ,  A61K31/33

CPC分类号： A61K31/135 ,  A61K31/165 ,  A61K31/24 ,  A61K31/415 ,  A61K31/44 ,  A61K31/445 ,  A61K31/505 ,  Y10S435/81 ,  Y10S514/816 ,  Y10S514/818

摘要： Methods of reversing local anesthesia are disclosed. The methods comprise administering a local anesthetic and alpha adrenergic receptor agonist to induce local anesthesia followed by reversing anesthesia with a low dose of an alpha adrenergic receptor antagonist. Also disclosed are kits comprising a local anesthetic, an alpha adrenergic receptor agonist and a low dose of an alpha adrenergic receptor antagonist.

公开(公告)号：US06566338B1

公开(公告)日：2003-05-20

申请号：US09685689

申请日：2000-10-11

申请人： Eckard Weber ,  Gordon B. Mills ,  Douglas R. Green

发明人： Eckard Weber ,  Gordon B. Mills ,  Douglas R. Green

IPC分类号： A61K3805

CPC分类号： A61K38/05

摘要： The use of caspase inhibitors for treating, ameliorating, and preventing non-cancer cell death during chemotherapy and radiation therapy and for treating and ameliorating the side effects of chemotherapy and radiation therapy of cancer is disclosed.

摘要翻译： 公开了使用半胱天冬酶抑制剂治疗，改善和预防化疗和放射治疗期间的非癌细胞死亡以及用于治疗和改善癌症的化疗和放射治疗的副作用。

公开(公告)号：US20120093889A1

公开(公告)日：2012-04-19

申请号：US13330395

申请日：2011-12-19

申请人： Anthony McKinney ,  Gary Tollefson ,  Eckard Weber ,  Rick Soltero

发明人： Anthony McKinney ,  Gary Tollefson ,  Eckard Weber ,  Rick Soltero

IPC分类号： A61K9/00 ,  A61K31/485 ,  A61K31/423 ,  A61P3/04

CPC分类号： A61K9/209 ,  A61K9/0002 ,  A61K9/2018 ,  A61K9/2054 ,  A61K31/137 ,  A61K31/138 ,  A61K31/155 ,  A61K31/35 ,  A61K31/357 ,  A61K31/42 ,  A61K31/423 ,  A61K31/485 ,  A61K31/551 ,  A61K31/5513 ,  A61K45/06 ,  A61K47/26 ,  A61K2300/00

摘要： In one embodiment a layered pharmaceutical formulation includes two or more pharmaceutical layers and an intermediate layer disposed between at least two of the two or more pharmaceutical layers, the intermediate layer configured to dissolve in vivo to thereby leave the two or more pharmaceutical layers substantially intact. In one embodiment, an active pharmaceutical ingredient in at least one of the pharmaceutical layers is selected from bupropion, zonisamide, naltrexone, topiramate, phentermine, metformin, olanzapine and fluoxetine.

摘要翻译： 在一个实施方案中，分层药物制剂包含两个或更多个药物层和设置在两个或更多个药物层中的至少两个之间的中间层，所述中间层被配置为在体内溶解，从而使两个或更多个药物层基本上保持完好。 在一个实施方案中，至少一个药物层中的活性药物成分选自安非他酮，唑尼沙胺，纳曲酮，托吡酯，芬特明，二甲双胍，奥氮平和氟西汀。

公开(公告)号：US20100190793A1

公开(公告)日：2010-07-29

申请号：US12751970

申请日：2010-03-31

申请人： Eckard Weber ,  Michael Alexander Cowley

发明人： Eckard Weber ,  Michael Alexander Cowley

IPC分类号： A61K31/485 ,  A61K31/451 ,  A61K31/135 ,  A61K31/5375 ,  A61P3/00

CPC分类号： A61K31/485 ,  A61K31/135 ,  A61K31/137 ,  A61K31/138 ,  A61K45/06 ,  A61P3/04 ,  Y10S514/909 ,  Y10S514/964 ,  A61K2300/00

摘要： Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance α-MSH activity.

摘要翻译： 公开了用于影响体重减轻的组合物，其包含第一化合物和第二化合物，其中第一化合物是阿片样物质拮抗剂，第二化合物引起黑皮质素3受体（MC3-R）或黑皮质素4受体（MC4-R） ）与正常生理条件相比。 还公开了影响体重减轻，增加能量消耗，增加个体饱腹感或抑制个体食欲的方法，包括鉴定有需要的个体并治疗该个体以拮抗阿片受体活性和增强α-MSH活性 。

公开(公告)号：US20080113026A1

公开(公告)日：2008-05-15

申请号：US11937421

申请日：2007-11-08

申请人： Anthony McKinney ,  Gary Tollefson ,  Eckard Weber ,  Rick Soltero

发明人： Anthony McKinney ,  Gary Tollefson ,  Eckard Weber ,  Rick Soltero

IPC分类号： A61K9/24

CPC分类号： A61K9/209 ,  A61K9/0002 ,  A61K9/2018 ,  A61K9/2054 ,  A61K31/137 ,  A61K31/138 ,  A61K31/155 ,  A61K31/35 ,  A61K31/357 ,  A61K31/42 ,  A61K31/423 ,  A61K31/485 ,  A61K31/551 ,  A61K31/5513 ,  A61K45/06 ,  A61K47/26 ,  A61K2300/00

摘要： In one embodiment a layered pharmaceutical formulation includes two or more pharmaceutical layers and an intermediate layer disposed between at least two of the two or more pharmaceutical layers, the intermediate layer configured to dissolve in vivo to thereby leave the two or more pharmaceutical layers substantially intact. In one embodiment, an active pharmaceutical ingredient in at least one of the pharmaceutical layers is selected from bupropion, zonisamide, naltrexone, topiramate, phentermine, metformin, olanzapine and fluoxetine.

摘要翻译： 在一个实施方案中，分层药物制剂包含两个或更多个药物层和设置在两个或更多个药物层中的至少两个之间的中间层，所述中间层被配置为在体内溶解，从而使两个或更多个药物层基本上保持完好。 在一个实施方案中，至少一个药物层中的活性药物成分选自安非他酮，唑尼沙胺，纳曲酮，托吡酯，芬特明，二甲双胍，奥氮平和氟西汀。

公开(公告)号：US20070275970A1

公开(公告)日：2007-11-29

申请号：US11779008

申请日：2007-07-17

申请人： Eckard Weber ,  Michael Cowley

发明人： Eckard Weber ,  Michael Cowley

IPC分类号： A61K31/443 ,  A61K31/4525

CPC分类号： A61K31/485 ,  A61K31/135 ,  A61K31/137 ,  A61K31/138 ,  A61K45/06 ,  A61P3/04 ,  Y10S514/909 ,  Y10S514/964 ,  A61K2300/00

摘要： Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance α-MSH activity.

公开(公告)号：US07229630B2

公开(公告)日：2007-06-12

申请号：US10465810

申请日：2003-06-20

申请人： Andrew X. Chen ,  Julius Knowles ,  Eckard Weber

发明人： Andrew X. Chen ,  Julius Knowles ,  Eckard Weber

IPC分类号： A61K9/08 ,  A61K47/12 ,  A61K47/18

CPC分类号： A61K31/4709 ,  A61K31/4745 ,  Y10S514/818 ,  A61K2300/00

摘要： The present invention provides compositions and stable liquid formulations comprising alpha adrenergic receptor antagonists and use thereof for increasing blood flow. In one embodiment, the stable liquid formulations of this invention are useful for reversing the effects of an anesthetic agent, preferably a long-lasting local anesthetic agent administered in conjunction with an alpha adrenergic receptor agonist.

摘要翻译： 本发明提供包含α-肾上腺素能受体拮抗剂的组合物和稳定的液体制剂及其用于增加血流量的用途。 在一个实施方案中，本发明的稳定的液体制剂可用于逆转麻醉剂，优选与α肾上腺素能受体激动剂联合施用的持久的局部麻醉剂的作用。

公开(公告)号：US20060058293A1

公开(公告)日：2006-03-16

申请号：US11194201

申请日：2005-08-01

申请人： Eckard Weber ,  Michael Cowley

发明人： Eckard Weber ,  Michael Cowley

IPC分类号： A61K31/5377 ,  A61K31/454 ,  A61K31/415 ,  A61K31/195 ,  A61K31/137

CPC分类号： A61K31/135 ,  A61K31/137 ,  A61K31/195 ,  A61K31/415 ,  A61K31/454 ,  A61K31/5377 ,  A61K45/06 ,  A61K2300/00

摘要： Disclosed are compositions for affecting weight loss comprising bupropion and a second compound, where the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions, antagonizes cannabinoid receptor activity, or is useful in the treatment of bipolar disorders. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual with a combination of bupropion and a compound that enhances α-MSH activity, antagonizes cannabinoid receptor activity, or is useful in the treatment of bipolar disorders.

摘要翻译： 公开了用于影响体重减轻的组合物，其包含安非他酮和第二化合物，其中第二化合物引起黑素皮质素3受体（MC3-R）或黑皮质素4受体（MC4-R）与正常生理条件相比更大的激动作用，拮抗大麻素受体 活动，或用于治疗双相障碍。 还公开了影响体重减轻，增加能量消耗，增加个体饱腹感或抑制个体食欲的方法，其包括鉴定需要的个体和用安非他酮和增强α-淀粉样化合物的组合治疗该个体的方法， MSH活性，拮抗大麻素受体活性，或用于治疗双相障碍。

公开(公告)号：US20050203099A1

公开(公告)日：2005-09-15

申请号：US11082968

申请日：2005-03-18

申请人： Andrew Chen ,  Julius Knowles ,  Eckard Weber

发明人： Andrew Chen ,  Julius Knowles ,  Eckard Weber

IPC分类号： A61K31/4709 ,  A61K31/4745 ,  A61K31/517

CPC分类号： A61K31/4709 ,  A61K31/4745 ,  Y10S514/818 ,  A61K2300/00

摘要： The present invention provides compositions and stable liquid formulations comprising alpha adrenergic receptor antagonists and use thereof for increasing blood flow. In one embodiment, the stable liquid formulations of this invention are useful for reversing the effects of an anesthetic agent, preferably a long-lasting local anesthetic agent administered in conjunction with an alpha adrenergic receptor agonist.

摘要翻译： 本发明提供包含α-肾上腺素能受体拮抗剂的组合物和稳定的液体制剂及其用于增加血流量的用途。 在一个实施方案中，本发明的稳定的液体制剂可用于逆转麻醉剂，优选与α肾上腺素能受体激动剂联合施用的持久的局部麻醉剂的作用。

公开(公告)号：US20050165098A1

公开(公告)日：2005-07-28

申请号：US11081641

申请日：2005-03-17

申请人： Eckard Weber ,  Howard Katz

发明人： Eckard Weber ,  Howard Katz

IPC分类号： A61K45/06 ,  A61K20060101 ,  A61K31/135 ,  A61K31/137 ,  A61K31/165 ,  A61K31/166 ,  A61K31/167 ,  A61K31/24 ,  A61K31/415 ,  A61K31/417 ,  A61K31/44 ,  A61K31/445 ,  A61K31/505 ,  A61K38/46 ,  A61P23/02 ,  A61P43/00 ,  A61K31/33

CPC分类号： A61K31/135 ,  A61K31/165 ,  A61K31/24 ,  A61K31/415 ,  A61K31/44 ,  A61K31/445 ,  A61K31/505 ,  Y10S435/81 ,  Y10S514/816 ,  Y10S514/818

摘要： Methods of reversing local anesthesia are disclosed. The methods comprise administering a local anesthetic and alpha adrenergic receptor agonist to induce local anesthesia followed by reversing anesthesia with a low dose of an alpha adrenergic receptor antagonist. Also disclosed are kits comprising a local anesthetic, an alpha adrenergic receptor agonist and a low dose of an alpha adrenergic receptor antagonist.